EA032263B1 - Применение ингибиторов ccr3 - Google Patents

Применение ингибиторов ccr3 Download PDF

Info

Publication number
EA032263B1
EA032263B1 EA201401083A EA201401083A EA032263B1 EA 032263 B1 EA032263 B1 EA 032263B1 EA 201401083 A EA201401083 A EA 201401083A EA 201401083 A EA201401083 A EA 201401083A EA 032263 B1 EA032263 B1 EA 032263B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chloride
treatment
eosinophilic
alkyl
disease
Prior art date
Application number
EA201401083A
Other languages
English (en)
Russian (ru)
Other versions
EA201401083A1 (ru
Inventor
Майкл Чадхем Найвенс
Тьерри Буйссу
Рольф Гёггель
Петер Зайтер
Original Assignee
Алкахест, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA032263(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Алкахест, Инк. filed Critical Алкахест, Инк.
Publication of EA201401083A1 publication Critical patent/EA201401083A1/ru
Publication of EA032263B1 publication Critical patent/EA032263B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
EA201401083A 2012-04-03 2013-04-02 Применение ингибиторов ccr3 EA032263B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (2)

Publication Number Publication Date
EA201401083A1 EA201401083A1 (ru) 2015-03-31
EA032263B1 true EA032263B1 (ru) 2019-05-31

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401083A EA032263B1 (ru) 2012-04-03 2013-04-02 Применение ингибиторов ccr3

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP4389217A3 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20220132012A (enExample)
CN (2) CN110384699A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
EP3449866B1 (en) 2016-11-24 2021-10-20 Kirishima Seiko Co., Ltd. Orthodontic appliance
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
EA201992356A1 (ru) * 2017-04-05 2020-03-23 Алкахест Инк. Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
CA3076017A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US12692301B2 (en) 2020-06-11 2026-07-28 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US20090123375A1 (en) * 2007-10-09 2009-05-14 University Of Kentucky Research Foundation CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US20090123375A1 (en) * 2007-10-09 2009-05-14 University Of Kentucky Research Foundation CCR3 Inhibition for Ocular Angiogenesis and Macular Degeneration
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists
WO2012045803A1 (en) * 2010-10-07 2012-04-12 Boehringer Ingelheim International Gmbh Co-crystals and salts of ccr3-inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATSUNOBU TAKEDA, JUDIT Z. BAFFI, MARK E. KLEINMAN, WON GIL CHO, MIHO NOZAKI, KIYOSHI YAMADA, HIROKI KANEKO, ROMULO J. C. ALBUQUERQ: "CCR3 is a target for age-related macular degeneration diagnosis and therapy", NATURE, MACMILLAN JOURNALS LTD., LONDON, vol. 460, no. 7252, 9 July 2009 (2009-07-09), London, pages 225 - 30, XP002693828, ISSN: 0028-0836, DOI: 10.1038/NATURE08151 *
BACHERT C, WATELET J B, GEVAERT P, VAN CAUWENBERGE P.: "Pharmacological management of nasal polyposis", DRUGS, ADIS INTERNATIONAL LTD., NZ, vol. 65, no. 11, 1 January 2005 (2005-01-01), NZ, pages 1537 - 1552, XP002697885, ISSN: 0012-6667, DOI: 10.2165/00003495-200565110-00006 *
BLANCHARD C, ET AL.: "Eotaxin-3 and a Uniquely Conserved Gene-Expression profile in Eosinophilic Esophagitis", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 116, no. 2, 1 February 2006 (2006-02-01), GB, pages 536 - 547, XP003003549, ISSN: 0021-9738, DOI: 10.1172/JCI26679 *

Also Published As

Publication number Publication date
KR20250133980A (ko) 2025-09-09
US20170319567A1 (en) 2017-11-09
AU2013245027B2 (en) 2017-10-12
ES2987267T3 (es) 2024-11-14
KR20220132012A (ko) 2022-09-29
BR112014023795A2 (enExample) 2017-06-20
PT2833884T (pt) 2020-08-26
EP4389217A3 (en) 2024-08-28
NZ628882A (en) 2016-05-27
SI2833884T1 (sl) 2020-10-30
EA201401083A1 (ru) 2015-03-31
CN104220073A (zh) 2014-12-17
US20130261153A1 (en) 2013-10-03
JP2018080183A (ja) 2018-05-24
ES2811554T3 (es) 2021-03-12
WO2013149986A1 (en) 2013-10-10
PL2833884T3 (pl) 2020-11-02
BR112014023795A8 (pt) 2017-10-10
EP4389217A2 (en) 2024-06-26
JP2015512432A (ja) 2015-04-27
HUE051648T2 (hu) 2021-03-29
MX2014011786A (es) 2014-12-05
KR20200044988A (ko) 2020-04-29
DK2833884T3 (da) 2020-08-10
IL234262A (en) 2017-10-31
CN110384699A (zh) 2019-10-29
US20200375971A1 (en) 2020-12-03
KR20140144200A (ko) 2014-12-18
LT2833884T (lt) 2020-09-10
CA2869269C (en) 2020-06-30
HRP20201165T1 (hr) 2020-12-11
AU2013245027A1 (en) 2014-09-11
EP3763369B1 (en) 2024-02-28
EP2833884B1 (en) 2020-05-20
CL2014002523A1 (es) 2015-01-23
BR112014023795B1 (pt) 2021-09-08
CA2869269A1 (en) 2013-10-10
PH12014502239A1 (en) 2014-12-15
SMT202000499T1 (it) 2020-11-10
EP2833884A1 (en) 2015-02-11
RS60665B1 (sr) 2020-09-30
CY1123222T1 (el) 2021-10-29
EP3763369A1 (en) 2021-01-13
US20150099783A1 (en) 2015-04-09
ZA201406082B (en) 2019-01-30
KR20210063481A (ko) 2021-06-01
IN2014DN06989A (enExample) 2015-04-10
US20160081998A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
AU2013245027B2 (en) Use of CCR3-inhibitors
JP2017081959A (ja) 免疫関連疾患及び炎症性疾患の治療における３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンの使用
EA020987B1 (ru) Ассоциация между 4-{3-[цис-гексагидроциклопента[c]пиррол-2(1h)-ил]пропокси}бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
EA021461B1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
JP2013237709A (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
WO2012133489A1 (ja) 神経性疾患の治療又は予防のための医薬組成物
JP2012006918A (ja) イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP2007518768A (ja) 有機化合物の組み合わせ物
JP5978472B2 (ja) 耳鳴患者の治療用の薬剤
JP5366807B2 (ja) Ｔ細胞のＴｈ１細胞への分化抑制剤
HK40015701A (en) Use of ccr3-inhibitors
WO2007010946A1 (ja) 滑膜細胞増殖抑制剤
CN104981243A (zh) 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼后段疾病的预防或治疗剂
US20090203701A1 (en) Prophylactic and/or therapeutic agent for rheumatoid arthritis
WO2001058488A1 (en) Remedies for sjoegren's syndrome
JPWO2007049732A1 (ja) 関節リウマチの予防及び／又は治療法